[Acute non-lymphatic leukemia in children].

Area of Science:

• Pediatric Hematology Oncology
• Clinical Cancer Research
• Leukemia Treatment Outcomes

Context:

• Acute non-lymphoblastic leukemia (ANLL) is a significant pediatric malignancy.
• Treatment protocols and outcomes for ANLL in children have evolved over time.
• Understanding historical treatment data is crucial for advancing pediatric leukemia care.

Purpose:

• To analyze the treatment strategies and remission rates for pediatric ANLL over an 11-year period.
• To evaluate the impact of evolving chemotherapy regimens and immunotherapy on ANLL patient outcomes.
• To identify trends in complete remission (CR) achievement and remission duration based on treatment era.

Summary:

• A cohort of 40 children diagnosed with ANLL between 1970 and 1981 were analyzed.
• Patients received varying combination chemotherapies, with later groups benefiting from more standardized protocols (LAM-5, TRAP, COAP, LAM 80, AIL).
• Complete remission rates increased from 45% in the early period to 76% in the later period, with median remission duration improving from 5 to 17 months.

Impact:

• Demonstrates a clear correlation between evolving treatment protocols and improved outcomes in pediatric ANLL.
• Highlights the importance of standardized chemotherapy and the potential role of immunotherapy in achieving durable remissions.
• Provides valuable historical data for comparative studies and future research in pediatric leukemia.